ArticleBrain & spine2025
Treatment decisions for intermediate-sized brain metastases in or near the motor cortex among the neuro-oncology community.
Article in Brain & spine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Currently, there is lack of consensus regarding the optimal treatment strategy (surgery versus radiotherapy) for intermediate-sized (2-4 cm) brain metastases (BM), especially those located in or near the motor cortex. This survey aims to gain insight into treatment decisions for these BM among the Dutch multidisciplinary neuro-oncology community. Methods: An electronic survey was distributed among neurosurgeons, radiation oncologists, neurologists, and medical oncologists in The Netherlands. The survey comprised 13 questions regarding physician's practices and questions about treatment decisions for BM in or near the motor cortex using statements and three theoretical patient cases. Results: Tumor size (n = 34, 89 %), degree of neurological deficit (n = 31, 82 %), and the need for (temporarily) discontinuation of immunotherapy because of dexamethasone dependence (n = 30, 79 %) were highlighted as the most important factors to steer the treatment decision to radiotherapy or surgery. When divided by specialty, 15 neurologists (33 %), 14 radiation oncologists (30 %), 12 neurosurgeons (26 %), and 5 medical oncologists (11 %), some variability about the importance of factors exists. The respondents suggested a median cutoff size of 3,5 cm for conducting surgery on BM. Conclusion: Surgical resection is preferred in patients with larger tumors, with neurologic symptoms that are unresponsive to dexamethasone, and in patients receiving immunotherapy. Future investigations should compare the effectiveness of surgical resection and stereotactic radiosurgery, and the effects on survival and quality of life in patients with BM in or near the motor cortex in a prospective and preferable randomized manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.